
Loading, please wait...

Loading, please wait...

The FSSAI food labeling norms are undergoing a significant overhaul to include non-retail and bulk food packages under mandatory disclosure rules. Starting July 1, 2027, the Food Safety and Standards Authority of India (FSSAI) will enforce strict requirements for large packs used by distributors and caterers. Consequently, this move aims to close a long-standing gap in the food safety system by ensuring full transparency. Previously, these large containers often lacked critical details. However, every package must now disclose the product name, license number, and manufacturer details clearly.
The regulator requires that every bulk package displays batch numbers and storage instructions where necessary. If a container holds multiple items, each product needs a separate listing. Furthermore, businesses must ensure full traceability even when labels are not feasible. They can achieve this through electronic systems or documentation for transport containers. This ensures that food safety remains uncompromised throughout the supply chain. Additionally, the rules mandate that bulk packs clearly state they are not for direct retail sale. This prevents unauthorized diversion into the consumer market. Therefore, the information must be prominent and tamper-evident to maintain integrity.
The notification also fine-tunes nutrition-related disclosures for specific categories. For instance, infant foods are now exempt from %RDA declarations per serving. Similarly, nutraceuticals in tablet form can skip macronutrient details if the energy contribution is negligible. Moreover, the FSSAI has provided a clearer definition for minimally processed foods like pulses and cereals. Consumer warnings have also become more stringent. For example, pan masala advertisements must include audible or visible warnings. Products with artificial sweeteners must now specify restrictions for children and pregnant women. These changes represent a major step toward better public health outcomes.
Q1: When do the new FSSAI food labeling norms take effect?
The updated regulations for bulk and non-retail food packs will officially take effect on July 1, 2027.
Q2: What specific information must appear on bulk food packages?
Packages must include the product name, FSSAI license, batch number, manufacturer details, and a notice stating the item is not for direct retail sale.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


FSSAI mandates strict labeling for bulk food packs from July 2027, enhancing traceability and nutrition transparency for products used by hotels and caterer...
6 months ago

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

In high-risk pulmonary embolism complicated by severe anemia and active uterine bleeding, systemic thrombolysis is contraindicated. Large-bore aspiration thrombectomy provides rapid hemodynamic rescue without fibrinolysis, supported by inferior vena cava filter placement and multidisciplinary critical care.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today